Lupus News and Research

Latest Lupus News and Research

Researchers reveal link between the microbiome of young mice and later onset of autoimmune disease

Researchers have revealed that the colonization of the gut of young mice by certain types of bacteria can lead to immune responses later in life that are linked to disease.

19 Jan 2015

PTEN protein helps prevent autoimmune diseases

St. Jude Children's Research Hospital scientists have discovered that a protein widely known for suppressing tumor formation also helps prevent autoimmune diseases and other problems by putting the brakes on the immune response.

15 Jan 2015

Asian and Hispanic patients with lupus have lower mortality rates

A new study by researchers from Brigham and Women's Hospital in Boston, Massachusetts reveals that Asian and Hispanic patients with systemic lupus erythematosus (SLE) have lower mortality rates compared to Black, White, or Native Americans with the disease.

15 Jan 2015

Fat cells below skin help protect from bacteria, say researchers

When it comes to skin infections, a healthy and robust immune response may depend greatly upon what lies beneath. In a new paper published in the January 2, 2015 issue of Science, researchers at the University of California, San Diego School of Medicine report the surprising discovery that fat cells below the skin help protect us from bacteria.

2 Jan 2015

Anthera Pharmaceuticals to host Lupus symposium in San Francisco

Anthera Pharmaceuticals, Inc. today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.

31 Dec 2014

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease.

30 Nov 2014

BIDMC's George Tsokos receives two prestigious awards at 2014 ACR Annual Scientific Meeting

George Tsokos, MD, Chief of Rheumatology at Beth Israel Deaconess Medical Center and a national leader in the field of lupus research was honored by both the Lupus Foundation of America and the American College of Rheumatology with two prestigious awards presented during the 2014 ACR Annual Scientific Meeting recently held in Boston.

23 Nov 2014

Scientists identify how ADAR1 gene mutation can lead to diseases

Scientists have discovered how a gene mutation can lead to diseases that occur when the immune system attacks the body by mistake.

18 Nov 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

SQI Diagnostics gets FDA clearance to market Celiac Panel in the US

SQI Diagnostics Inc. today announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States (US).

8 Nov 2014

Health benefits of modified formulation of curcumin supplements

The health benefits of over-the-counter curcumin supplements might not get past your gut, but new research shows that a modified formulation of the spice releases its anti-inflammatory goodness throughout the body.

7 Nov 2014

Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers have uncovered key steps involved in programmed cell death, offering new targets for the treatment of diseases including lupus, cancers and neurodegenerative diseases.

31 Oct 2014

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets.

31 Oct 2014

Lactobacillus-containing probiotics can improve lupus symptoms

Lactobacillus species, commonly seen in yogurt cultures, correlate, in the guts of mouse models, with mitigation of lupus symptoms, while Lachnospiraceae, a type of Clostridia, correlate with worsening, according to research published ahead of print in Applied and Environmental Microbiology.

21 Oct 2014

Scientists identify two microRNA molecules that control chronic inflammation

University of Utah scientists have identified two microRNA molecules that control chronic inflammation, a discovery that one day may help researchers prevent certain fatal or debilitating conditions before they start.

17 Oct 2014

Researchers identify two microRNA molecules that control chronic inflammation

16 Oct 2014

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono.

7 Oct 2014

Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials

Eli Lilly and Company announced today it will discontinue development of tabalumab -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns.

3 Oct 2014